Major Drug Pricing Deal Reached Between AstraZeneca and Trump Administration
In a significant move for U.S. healthcare, AstraZeneca has agreed to reduce the cost of prescription drugs for Medicaid. This agreement with the Trump administration follows similar actions by other pharmaceutical giants, signaling a shift in drug pricing strategies.
President Donald Trump announced the deal alongside AstraZeneca CEO Pascal Soriot at the White House. Soriot acknowledged the challenging nature of the negotiations, stating that Trump’s team kept him “up at night.”
The agreement entails AstraZeneca offering Medicaid the most-favored-nation pricing, ensuring that U.S. prices match the lowest available in developed countries. Trump highlighted that Americans have been paying exorbitantly high prices and expressed optimism that this deal could reduce costs to an unprecedented level.
This development mirrors a recent agreement with Pfizer, part of a broader initiative to address drug pricing under a May executive order by Trump. The order set a deadline for drug companies to lower prices or face governmental payment restrictions.
Trump commented on the deal’s importance, noting that the threat of tariffs played a role in bringing Soriot to the table. AstraZeneca, headquartered in Cambridge, United Kingdom, is known for its cancer treatments such as Tagrisso and Lynparza, generating over $7.5 billion in U.S. sales last year.
The company also announced a $4.5 billion investment in a new manufacturing facility in Virginia, expected to create 3,600 jobs initially. This project is part of a larger $50 billion investment plan in the U.S. by 2030, with a revenue goal of $80 billion, half from the United States.
AstraZeneca’s move follows a decision to halt expansion of a vaccine plant in the UK, citing reduced financial backing from the government. Meanwhile, the Trump administration is preparing a new platform, TrumpRX.gov, to facilitate direct drug purchases from manufacturers, featuring medications from both Pfizer and AstraZeneca.
The website, slated to launch in January 2026, prominently features images of Trump and is being developed by The National Design Studio, led by Airbnb co-founder Joe Gebbia.
